1. Home
  2. EVGO vs ALXO Comparison

EVGO vs ALXO Comparison

Compare EVGO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGO

EVgo Inc.

HOLD

Current Price

$1.46

Market Cap

195.6M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.70

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGO
ALXO
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.6M
205.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
EVGO
ALXO
Price
$1.46
$1.70
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$5.23
$3.50
AVG Volume (30 Days)
3.3M
627.3K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
24.39
26.36
EPS
N/A
N/A
Revenue
$54,588,000.00
N/A
Revenue This Year
$16.45
N/A
Revenue Next Year
$29.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
145.74
N/A
52 Week Low
$1.23
$1.05
52 Week High
$5.18
$2.66

Technical Indicators

Market Signals
Indicator
EVGO
ALXO
Relative Strength Index (RSI) 50.22 34.39
Support Level $1.42 $1.56
Resistance Level $1.52 $2.19
Average True Range (ATR) 0.09 0.10
MACD 0.02 -0.03
Stochastic Oscillator 79.31 2.26

Price Performance

Historical Comparison
EVGO
ALXO

About EVGO EVgo Inc.

EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: